Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof

a technology of chimeric antigen receptors and fibronectin, which is applied in the field of bcma-specific fibronectin type iii (fn3) domains, bcma-targeting chimeric antigen receptors, can solve the problem that scfvs are inherently more prone to biophysical challenges

Inactive Publication Date: 2022-02-03
JANSSEN BIOTECH INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009]The invention satisfies this need by providing BCMA-specific FN3 domains, BCMA-targeting CARs comprising the FN3 domains, engineered BCMA-targeting immune cells expressing the CARs, methods of making and methods of using thereof. When the BCMA-targeting CARs are expressed on the surface of pan T cells, the cells specifically kill BCMA-expressing tumor cell lines. Thus, the BCMA-targeting CARs of the invention can be used to effectively retarget T cells to kill BCMA-expressing cells in a highly specific manner.
[0010]While not wishing to be bound by theory, it is thought that the use of an FN3 domain, rather than an scFv, as the extracellular domain of a CAR will allow for more stable and controllable CAR molecules, because scFvs are inherently more prone to biophysical challenges. In addition, the small size of the FN3 domain will allow for better immunological synapse optimization and greater flexibility to target very specific domains of a TAA.

Problems solved by technology

While not wishing to be bound by theory, it is thought that the use of an FN3 domain, rather than an scFv, as the extracellular domain of a CAR will allow for more stable and controllable CAR molecules, because scFvs are inherently more prone to biophysical challenges.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
  • Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
  • Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

f FN3 Domain Libraries Against Recombinant BCMA Proteins by CIS Display

[0217]Two constructs for BCMA recombinant protein target antigen were purchased from AB Biosiences. One was BCMA protein alone (catalog #P011Xp), and the other was BCMA fused to the Fc domain of mouse IgG2a (catalog #P001F).

[0218]FN3 Domain CIS-Display Library Selection

[0219]CIS-display was used to select BCMA-binding FN3 domains from the TCL18, TCL19, TCL21, TCL23, and TCL24 libraries.

[0220]TCL19, TCL21 and TCL23 Tencon libraries (SEQ ID NO: 46) are randomized at positions within the C and F strands and within the CD and FG loops, with the distribution of amino acids occurring at these positions as shown in Table 2. TCL19 and TCL21 were designed to include an equal distribution of 18 natural amino acids at every position (5.55% of each), excluding only cysteine and methionine. TCL23 was designed such that each randomized position approximates the amino acid distribution found in the CDR-H3 loops of functional an...

example 2

of BCMA-Specific FN3 Domains for Binding to HEK293F Cells Transiently Expressing Human BCMA

[0236]Cell counts and cell viability of hBCMA-expressing HEK293F and Mock HEK293F cells were measured, and 25×106 of each cell type were spun down at 175 g for 5 min. The media was aspirated and replaced with 25 mL FACS buffer. 100,000 cells were seeded per well in two V-bottom 96-well plates per cell type, and the plates were kept on ice throughout the experiment. The samples were set up as follows:

[0237]hBCMA cells; 2 uM treatment

[0238]hBCMA cells; 0.2 uM treatment

[0239]Mock cells; 2 uM treatment

[0240]Mock cells; 0.2 uM treatment

[0241]Positive and negative antibody controls were included. 12.5 uL of control antibodies were added to 238.5 uL FACS buffer to achieve 5 uL antibody (2.5 ug) per 100 uL treatment volume. Buffer controls were also included. The buffer control wells contained only 250 uL FACS buffer.

[0242]The plates were spun at 1200 rpm for 5 min at 4° C. to pellet the cells. Buffer...

example 3

onse Curve (DRC) Assessment of Anti-BCMA FN3 Domains for Binding to HEK293F Cells Transiently Expressing Human BCMA

[0247]Ten 3-fold dilutions of FN3 domains were titrated in BD FACS buffer, with a starting concentration of 5 uM. Control samples were diluted in FACS buffer. Source plates, each with 7 FN3 domains in single-point dose titrations, were generated alongside a non-specific Tencon25 control for overlay onto HEK293F cells transiently expressing human BCMA. The assay controls included:

[0248]A Tencon25 dose-response curve series on each plate to measure non-specific binding;

[0249]Untreated cells stained with anti-His Alexa-488 to measure non-specific labeling;

[0250]Untreated cells with no anti-His antibody staining to measure absolute background;

[0251]A positive control of 1 uM of the FN3 domain referred to as ‘G10’ was used as a reference to control for plate-to-plate variability in signal intensity; and

[0252]Viability testing wells to troubleshoot apparent low viability.

[025...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
Login to view more

Abstract

BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.

Description

[0001]This application is a divisional of U.S. application Ser. No. 16 / 323,121, filed Feb. 4, 2019, now U.S. Pat. No. 11,096,998, which is a U.S. National Stage Application under 35 U.S.C. § 371 of International Patent Application No. PCT / US2017 / 050888, filed Sep. 11, 2017, which claims the benefit of U.S. Provisional Application No. 62 / 394,329, filed Sep. 14, 2016, the disclosure of each of which is incorporated by reference herein in its entirety.SEQUENCE LISTING[0002]This application incorporates by reference in its entirety the Computer Readable Form (CRF) of a Sequence Listing in ASCII text format submitted via EFS-Web. The Sequence Listing text file submitted via EFS-Web is entitled “14620-328-999 SL.txt”, created on Jul. 16, 2021, and having a size of 138,671 bytes.FIELD OF THE INVENTION[0003]The invention relates to BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00C07K16/28C12N15/82A61P35/00C07K14/525C07K14/705C07K14/75C07K14/78
CPCA61K39/0011C07K2319/31C12N15/8257A61P35/00C07K14/525C07K14/705C07K14/75C07K14/78C07K2317/24C07K2317/50C07K2319/03C07K2317/622C07K2319/033A61K2039/5158A61K2039/5156C07K2319/30C07K16/2878C12N5/0636C07K2317/92C07K2318/00C07K2319/02C12N2510/00
Inventor CHIN, CHEN NILEE, JOHNMCCABE, TIMOTHYMOONEY, JILLNASO, MICHAELSTROHL, WILLIAM
Owner JANSSEN BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap